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Background. Functional gastrointestinal disorders and fatigue may follow acute infections. This study aimed to
estimate the persistence, prevalence, and risk of irritable bowel syndrome and chronic fatigue 6 years after Giardia
infection.
Methods. We performed a controlled prospective study of a cohort of 1252 individuals who had laboratory-
conﬁrmed Giardia infection during a waterborne outbreak in 2004. In total, 748 cohort cases (exposed) and 878
matched controls responded to a postal questionnaire 6 years later (in 2010). Responses were compared to data
from the same cohort 3 years before (in 2007).
Results. The prevalences of irritable bowel syndrome (39.4%) by Rome III criteria and chronic fatigue (30.8%) in
the exposed group 6 years after giardiasis were signiﬁcantly elevated compared with controls, with adjusted relative
risks (RRs) of 3.4 (95% conﬁdence interval [CI], 2.9–3.9) and 2.9 (95% CI, 2.3–3.4), respectively. In the exposed
group, the prevalence of irritable bowel syndrome decreased by 6.7% (RR, 0.85 [95% CI, .77–.93]), whereas the prev-
alence of chronic fatigue decreased by 15.3% from 3 to 6 years after Giardia infection (RR, 0.69 [95% CI, .62–.77]).
Giardia exposure was a signiﬁcant risk factor for persistence of both conditions, and increasing age was a risk factor
for persisting chronic fatigue.
Conclusions. Giardia infection in a nonendemic setting is associated with an increased risk for irritable bowel
syndrome and chronic fatigue 6 years later. The prevalences of both conditions decrease over time, indicating that
this intestinal protozoan parasite may elicit very long-term, but slowly self-limiting, complications.
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Fatigue and gastrointestinal symptoms are common
manifestations of several infections and other diseases
[1, 2], In some cases, these symptoms may persist
after the infection has resolved [3–5]. Irritable bowel
syndrome (IBS) is characterized by prolonged
abdominal pain or discomfort combined with diarrhea
and/or constipation of variable intensity, and may occur
after gastroenteritis, including travelers’ diarrhea [3, 4].
Between 6% and 17% of IBS cases have been reported to
be preceded by gastroenteritis [6]. Some longitudinal
follow-up studies have been performed and support
gradual recovery of abdominal complaints after infec-
tious gastroenteritis. However, after 6 years of follow-
up, postinfectious IBS (PI-IBS) may persist in >50%
of cases [7, 8]. Similarly, fatigue has also been reported
to persist after acute infection, but long-term studies are
scarce [5, 9–11]. Long-term follow-up data of chronic
fatigue (CF) following enteric infections and its associ-
ation with PI-IBS has not been reported.
The ubiquitous protozoan intestinal parasite Giardia
lamblia is a frequent cause of waterborne gastroenteritis
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outbreaks in many countries, and it is commonly seen in re-
turning travelers with diarrheal disease [12]. During a water-
borne outbreak of G. lamblia gastroenteritis in Bergen,
Norway, in autumn 2004, approximately 2500 individuals
were treated for giardiasis [13]. Patients with persistent, metro-
nidazole-refractory giardiasis were successfully treated during
the initial follow-up [14]. Since the outbreak, all individuals
with laboratory-conﬁrmed giardiasis during the outbreak
(n = 1252) have been followed up, with special attention to pro-
longed postinfectious abdominal symptoms and fatigue [15–
19]. The main objective was to evaluate the prevalences and
relative risks of IBS and CF 6 years after Giardia infection; sec-
ondary objectives were to evaluate changes in prevalence from 3
to 6 years after infection and to evaluate risk factors for persis-
tence of these conditions.
METHODS
Participants
This study presents data from a prospective follow-up in 2010 of
a cohort of 1252 individuals 6 years after veriﬁed Giardia infec-
tion during a waterborne outbreak (exposed group). A random-
ly sampled 2:1 age- and sex-matched control group of 2504
individuals was established with the aid of Statistics Norway
during 2007, and made it possible to compare developments
over time in both groups. Table 1 shows details of the exposed
and control groups approached in October 2007 and October
2010. The study was approved by the Regional Committee for
Ethics in Medical Research (2010/721).
Variables
The primary outcome of this study was the presence of CF and
IBS 6 years after giardiasis in the Giardia-exposed and control
groups. Secondary outcomes were the changes in the prevalence
of CF and IBS and mean fatigue scores [20] in the exposed
group and the control group between 3 and 6 years after Giardia
infection, where those who had a condition at both time-points
were deﬁned as having a persistent condition. We also evaluated
factors potentially inﬂuencing persistence of CF and IBS from
2007 to 2010.
IBS was deﬁned using the Rome III criteria [21]. IBS limiting
or restricting daily activities at least “often” was termed “severe
IBS.”
Fatigue was measured using the validated 11-item Fatigue
Questionnaire [20]. To each of the 11 questions, there are 4 pos-
sible answers (“less than normal,” “as normal,” “more than nor-
mal,” “much more than normal”). These are scored (0, 1, 2, 3)
and added, giving a score range from 0 to 33. Responses are also
dichotomized (0 and 1 into 0, 2 and 3 into 1), and a total dichot-
omized score of ≥4 deﬁned CF, if symptoms lasted >6 months.
The combination of CF and a total fatigue score of ≥23 was
deﬁned as severe fatigue. The Fatigue Questionnaire was accept-
ed if ≥8 of the 11 questions were answered. Unanswered ques-
tions were assigned the same value as the mean of all responses
to that particular question. To describe the substantial overlap
of IBS and CF, we also analyzed prevalences of having only 1 of
the conditions or a combination of both.
Questions on the demographic variables sex, age (categorized
in 20-year groups), marital status, education level (3 categories),
and main occupation (4 categories) were also included in the
questionnaire. These variables were considered potential con-
founders. Sex was also considered a potential effect modiﬁer.
Analyses and Statistical Methods
Descriptive statistics are given as percentage, mean, and stan-
dard deviation (SD). Nonresponders were only included in
nonresponder analyses and compared with responders. Partic-
ipants with missing data were excluded from analyses pertain-
ing to that speciﬁc variable. For associations in 2 × k tables, we
used Pearson exact χ2 test. Continuous variable means were
compared between groups using Gosset paired and unpaired
t test [22].
Prevalences at 6 years are compared using relative risks (RRs)
with 95% conﬁdence intervals (CIs). IBS and CF were analyzed
separately with respect to the risk factors and possible interac-
tions using multiple logistic regression, producing adjusted
odds ratios (ORs) with 95% CIs. In this model, backward step-
wise selection was applied removing variables with a P value
>.05; thus, variables that did not inﬂuence the results were ex-
cluded. Also, it was checked that removing a variable did not
change the estimated effects of the remaining variables in a
Table 1. Description of the Cohorts Available for Analyses of
Irritable Bowel Syndrome and Chronic Fatigue 3 and 6 Years
After the 2004 Giardia Outbreak in Norway
Cohort Exposeda Controlsb
Total
No.
Target population 2007 [19] 1252 (100.0) 2504 (100.0) 3756
Study population 2007 817 (65.3) 859 (34.3) 1676
Lost to follow-upc 13 (1.0) 60 (2.4) 73
Target population 2010 1239 (100.0) 2444 (100.0) 3683
Questionnaires returned
2010
748 (60.4) 888 (36.3) 1638
Giardia during outbreak 7 (0.3)
Incomplete/ambiguous
response
3 (0.1)
Study population in 2010 748 (60.4) 878 (35.9) 1626
Responded in 2007 and in
2010
601 (48.5) 559 (22.9) 1160
Data are presented as No. (%).
a Giardia exposed.
b Age- and sex-matched individuals from the general population in Bergen,
Norway.
c Emigrated or died between 2007 and 2010, or address not found in 2010.
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substantial way. Because ORs and RRs correspond poorly when
outcome prevalence is high, we converted adjusted ORs from
logistic regression analyses to RRs and corresponding CIs by
the method of Zhang and Yu [23]. The ratio of RRs was calcu-
lated using the formula of Altman and Bland [24], using the RR
from 3 to 6 years in the exposed group as a reference.
The attributable fraction among the exposed (AFE)—that is,
the proportion of the outcome conditions in the exposed group
that can be attributed to the Giardia infection—was calculated as
a percentage given by the formula AFE%= (1–1/RR) × 100 [25].
A binary logistic regression analysis using generalized estimat-
ing equations (GEEs) was used to evaluate changes in IBS and CF
prevalence from 3 to 6 years, making it possible to include data
from all respondents at both time-points and accounting for cor-
relation between repeated measures and the matched design.
Comparisons of new and recovered cases from 2007 to 2010
were done using McNemar test for symmetry. Evaluation of risk
factors for persistence of CF or IBS from 2007 to 2010 was done
among individuals who had responded at both time points
using multiple logistic regression analysis with respect to age,
sex, and exposure.
The level of statistical signiﬁcance was set at .05, and all tests
were 2-sided. All analyses were done using IBM SPSS Statistics
version 19.
RESULTS
In total, 748 (60.4%) exposed individuals and 878 (35.9%) con-
trols responded to the 6-year questionnaire (Table 1). More
nonresponders to the 6-year questionnaire were male (43.1%)
compared with responders (33.7%; P < .001) and they were
younger (mean age, 36.9 years) than responders (mean age,
38.2 years; P < .001). Table 2 shows the characteristics of re-
sponders in the exposed and control groups.
Six years after the outbreak, the prevalence of CF was 30.8%
(226/733) in the exposed group and 11.0% (96/874) in controls,
giving an adjusted RR of 2.9 after Giardia exposure. The frac-
tion of CF (AFE) attributable to previous giardiasis was 65%
(95% CI, 57.3%–70.8%) in the exposed group.
The prevalence of IBS was 39.4% (291/739) in the exposed
group and 11.6% (101/870) in controls. This gave an adjusted
RR of 3.4 in the Giardia-exposed group (Table 3). For IBS,
Table 2. Characteristics of Individuals Responding to a Questionnaire 6 Years After Acute Giardiasis, and of Those Responding to
Questionnaires at Both 3 and 6 Years After the 2004 Giardia Outbreak in Norway
Characteristics
All Responders in 2010 (n = 1626) Responders in 2007 and 2010 (n = 1160)
Exposed, No. (%) Controls, No. (%) P Valuea Exposed, No. (%) Controls, No. (%) P Valuea
Female sex 502 (67.1) 578 (65.8) .599 410 (68.2) 380 (68.0) .950
Age, y
Mean (range) 38.1 (7–97) 38.9 (6–85) .283 39.2 (8–97) 40.0 (7–83) .313
0–19 29 (3.9) 37 (4.2) .288 18 (3.0) 12 (2.1) .187
20–39 451 (60.3) 516 (58.8) 347 (57.7) 325 (58.1)
40–59 207 (27.7) 238 (27.1) 180 (30.0) 164 (29.3)
60–79 48 (6.4) 78 (8.9) 44 (7.3) 54 (9.7)
80–99 13 (1.7) 9 (1.0) 12 (2.0) 4 (0.7)
Marital status
Single 202 (27.3) 184 (21.1) .017 157 (26.3) 98 (17.7) .002
Married 499 (67.5) 631 (72.3) 405 (67.7) 428 (77.3)
Divorced 28 (3.8) 47 (5.4) 27 (4.5) 23 (4.2)
Widowed 10 (1.4) 11 (1.3) 9 (1.5) 5 (0.9)
Education
Primary school 35 (4.7) 72 (8.3) <.001 29 (4.9) 32 (5.8) .056
Secondary school 136 (18.4) 225 (26.0) 112 (18.8) 133 (24.1)
University 567 (76.8) 567 (65.6) 455 (76.3) 387 (70.1)
Main occupation
Worker 561 (76.2) 688 (78.8) .121 450 (75.5) 458 (82.2) .005
Student 63 (8.6) 78 (8.9) 50 (8.4) 37 (6.6)
Unemployed/retired 89 (12.1) 94 (10.8) 78 (13.3) 58 (10.4)
Other 23 (3.1) 13 (1.5) 18 (3.0) 4 (0.7)
a P values derived from the exact χ2 test from 2 × k table for categorical data, and from t test for independent samples for the mean age.
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the AFE due to giardiasis was 70.5% (95% CI, 65.1%–74.6%).
Relative risks for the subgroups of severe IBS and severe CF
were also elevated in the exposed group (Table 3).
The mean total fatigue score was 14.8 (SD, 5.5) in the exposed
group and 12.2 (SD, 4.2) in controls (P < .001). The mean total
fatigue scores in 2007 and in 2010 showed a reduction from 16.0
to 14.8 in the exposed group (P < .001) and no change in the
control group, from 12.0 to 11.9 (P = .731).
In both groups, CF and IBS were associated with each other.
In the exposed group, 47.4% of those with IBS also had CF,
whereas 19.8% of those without IBS had CF (P < .001). A similar
pattern was seen in the controls, with corresponding ﬁgures of
29.0% and 8.4% (P < .001).
Female sex was found to be a risk factor for IBS in the control
group (females, 13.8% and males, 7.4%; P = .007), but not in the
Giardia-exposed cohort ( females, 41.0% and males, 36.1%;
P = .228). There was no signiﬁcant sex difference in CF preva-
lence in the 2 groups; CF in exposed females was 31.6%, and in
males 29.3% (P = .55), whereas it was 11.8% in female controls
and 9.4% in male controls (P = .31).
We found a signiﬁcant decrease in prevalence of both IBS
(46.1%–39.4%) and CF (46.1%–30.8%) from 3 to 6 years in
the exposed group, but not among the controls (Table 4).
When comparing the changes in prevalence between the ex-
posed group and the controls with logistic regression analysis,
we found that the decrease in CF and severe CF from 3 to 6
years was signiﬁcantly different between the 2 groups, whereas
the change in IBS was not (Table 4).
Some of the participants fulﬁlled criteria for a condition in
2007 but not in 2010, indicating that they had “recovered.” Like-
wise, there were also “incident” cases of both conditions that
fulﬁlled the criteria in 2010 but not in 2007.
In the exposed group, recovery from IBS was signiﬁcantly
more common with 96 individuals (16.9%) no longer fulﬁlling
the criteria, whereas there were 53 (9.3%) incident cases
(P = .001). In the control group, 39 (7.1%) had recovered,
whereas 31 (5.7%) individuals had incident IBS (P = .403).
In the exposed group, 105 (18.3%) individuals had recovered
from CF, whereas 32 (5.6%) cases were incident (P < .001). In
controls, 42 (7.6%) individuals had recovered from CF and
there were 31 (5.6%) “incident” cases (P = .24).
Table 3. Prevalence of Irritable Bowel Syndrome and Chronic
Fatigue 6 Years After the 2004 Giardia Outbreak in Norway
Condition
All
No.
Exposed,
No. (%)
Controls,
No. (%)
Unadjusted
RR (95% CI)
Adjusteda
RR (95% CI)
IBS 1609 291 (39.4) 101 (11.6) 3.4 (2.8–4.2) 3.4 (2.9–3.9)
Severe
IBS
1595 53 (7.2) 18 (2.1) 3.5 (2.0–5.9) 3.1 (1.9–5.1)
CF 1607 226 (30.8) 96 (11.0) 2.8 (2.3–3.5) 2.9 (2.3–3.4)
Severe
CF
1607 66 (9.0) 23 (2.6) 3.4 (2.1–5.4) 3.1 (1.9–4.8)
Both IBS
and CF
1586 135 (18.6) 29 (3.3) 5.6 (3.8–8.2) 5.5 (3.8–7.7)
Only IBS 1586 150 (20.7) 71 (8.2) 2.5 (1.9–3.3) 2.5 (2.0–3.2)
Only CF 1586 87 (12.0) 64 (7.4) 1.6 (1.2–2.2) 1.7 (1.2–2.3)
Abbreviations: CF, chronic fatigue; CI, confidence interval; IBS, irritable bowel
syndrome; RR, relative risk.
a Adjusted for sex, age, level of education, marital status, and main occupation.
Table 4. Changes in Prevalences of Irritable Bowel Syndrome and Chronic Fatigue Including Subgroups and Combinations of These
Conditions at 3 Years and 6 Years After the 2004 Giardia Outbreak in Norway
Condition
Giardia Exposed Controls Between Groups
Ratio of RRc
(95% CI)3 ya No. (%) 6 y No. (%) % Change RRb (95% CI) 3 ya No. (%) 6 y No. (%) % Change RRb (95% CI)
IBS 355 (46.1) 291 (39.4) −6.7 0.85 (.77–.93) 155 (14.0) 101 (11.6) −2.4 0.84 (.69–1.11) 1.01 (.78–1.32)
Severe IBS 106 (13.8) 53 (7.2) −6.6 0.52 (.40–.60) 30 (2.7) 18 (2.1) −0.6 0.77 (.44–1.34) 0.68 (.37–1.23)
CF 366 (46.1) 226 (30.8) −15.3 0.69 (.62–.77) 134 (12.0) 96 (11.0) −1.0 0.91 (.72–1.13) 0.76 (.59–.98)
Severe CF 120 (15.1) 66 (9.0) −6.1 0.60 (.47–.75) 24 (2.1) 23 (2.6) 0.5 1.21 (.73–1.99) 0.49 (.28–.86)
Both IBS and CF 216 (28.6) 135 (18.6) −10.0 0.66 (.57–.77) 49 (4.5) 29 (3.3) −0.8 0.75 (.48–1.15) 0.88 (.56–1.41)
Only IBS 129 (17.1) 150 (20.7) 3.7 1.19 (.98–1.42) 104 (9.5) 71 (8.2) −1.0 0.89 (.68–1.15) 1.34 (.97–1.86)
Only CF 125 (16.6) 87 (12.0) −4.7 0.73 (.58–.92) 85 (7.7) 64 (7.4) −0.3 0.95 (.72–1.26) 0.77 (.54–1.10)
Abbreviations: CF, chronic fatigue; CI, confidence interval; IBS, irritable bowel syndrome; RR, relative risk.
a Data taken from Wensaas et al [19].
b RR with 95% CI for having the condition 6 years after Giardia infection compared to 3 years after. The RR was calculated from the odds ratio (OR) derived from
binary logistic regression analysis using generalized estimating equations (GEEs) for IBS and chronic fatiguewith only time as factors, and separately for exposed and
controls.
c Evaluation of the statistical significance of the difference between changes in exposed and controls by testing model effects in GEE for interaction between
exposure and time. The OR returned in this model was used to calculate the RR using the method of Zhang and Yu [23], and the ratio of RR was calculated by
the method of Altman and Bland [24].
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Prevalences of persisting IBS and CF were estimated among
the individuals who fulﬁlled the criteria for IBS or CF in 2007,
and who also responded in 2010 (Supplementary Table 1).
Among 251 exposed individuals with CF in 2007, 146
(58.2%) still had CF in 2010, whereas the corresponding ﬁg-
ures in controls were 16 of 58 (27.6%). In a logistic regression
model including sex, age, and Giardia exposure, we found that
Giardia exposure was signiﬁcantly associated with persisting CF
(RR, 2.13 [95% CI, 1.55–2.64]). Increasing age was associated
with increased risk for CF, with an RR of 1.43 (95% CI, 1.14–
1.69) in those 40–59 years of age, and an RR of 1.57 (95% CI,
1.12–1.91) in those 60–97 years of age, compared with the
younger (20–39 years) age group.
Among the 262 exposed individuals with IBS in 2007, 164
(63.1%) still reported IBS in 2010. Among the 64 controls with
IBS in 2007, 25 (39.1%) reported IBS again in 2010. Giardia ex-
posure was signiﬁcantly associated with persisting IBS in 2010
(RR, 1.64 [95% CI, 1.29–1.95]), whereas age and sex were not.
DISCUSSION
The main ﬁnding in this study was that there was a high preva-
lence of CF (30.8%) and IBS (39.4%) 6 years after laboratory-con-
ﬁrmed giardiasis and that these 2 conditions were strongly
associated. We also show that during the period from 3 to 6
years after the infection, the prevalence of both conditions de-
creased, and that recovery from chronic fatigue (15.3%) was
more pronounced than recovery from IBS (6.7%). In the exposed
group, both conditions were more persistent over time than in
controls. Persisting chronic fatigue was associated with higher age.
The strengths of this study are that it includes a high number
of participants, who all had laboratory-conﬁrmed infection with
the same pathogen during a short time period, and that ques-
tionnaires with identical questions were mailed to the same
groups of exposed and control individuals at the same time of
the year with a 3-year interval.
We judged that questions regarding preoutbreak fatigue and
IBS would be too prone to recall bias in the present study, but
from a previous study of 124 patients referred with severe abdom-
inal symptoms 2–18 months after the outbreak, we know that ap-
proximately 15% reported preoutbreak IBS-like symptoms [15].
Also, we found it questionable whether it would be correct to ex-
clude persons with preoutbreak fatigue and/or IBS. Treating the
whole Giardia-exposed cohort as a group has its merits, as the
Giardia infection may have modulated preexisting fatigue or IBS.
The higher percentage of women among the exposed can
partly be explained by women drinking more tap water [13].
There is a possibility that those in the exposed group had a
stronger tendency to consult the health services, given that
they were selected based on consultation and sampling during
the outbreak, compared with the controls that were randomly
chosen among the population. This might again inﬂuence the
way they evaluated their health and how they answered the
questionnaire, and to some extent account for the high preva-
lences of CF and IBS. However, from follow-up data, we know
that the response rate of the initially hospital-referred individu-
als, presumably experiencing more severe symptoms, was sim-
ilar to that of nonreferred individuals within the exposed group.
Sampling bias is possible, as the response rate differs between
the 2 groups. Although the response rate ideally should be higher
in the control group, the prevalences of CF and IBS at 3 and 6
years are comparable to previous Norwegian population-based
studies [26, 27]. The response rate of 60.4% in the exposed
group 6 years after the outbreak is acceptable, but there still
could be a bias toward responders having and reporting more
symptoms than nonresponders, and this relationship may be dif-
ferent in the control group. However, we do not ﬁnd it plausible
that this could account for the high RR among the exposed group.
Chronic giardiasis may give an IBS-like clinical picture. Dur-
ing the 2 years after the outbreak, patients with persisting symp-
toms in this cohort were thoroughly investigated in this respect
at the hospital or by their general practitioners. All positive
cases identiﬁed were successfully treated [14], and the carrier
status in the exposed general population was very low [28].
Five years after the outbreak, chronic giardiasis was assessed
in this cohort by polymerase chain reaction of stool samples
from 53 exposed persons with long-term CF and/or IBS and
20 exposed persons without sequelae, and none were found to
be positive [29, 30]. We therefore are convinced that the preva-
lence of chronic giardiasis in the exposed group is very low.
Interpretation
PI-IBS may follow bacterial [7, 31] and parasite-induced gastro-
enteritis [19, 32, 33], as well as viral disease [34]. Studies after an
outbreak of bacterial gastroenteritis in Walkerton, Canada,
showed the prevalence of PI-IBS to be 36% by Rome I criteria
2–3 years after infection [35]. Six years after, the prevalence had
decreased to 22% [7]. Our data show a somewhat higher
prevalence at both 3 and 6 years even when correcting for the
background IBS prevalence present in our data. The difference
in PI-IBS prevalence may be inﬂuenced by different IBS criteria
used (Rome I vs Rome III), selection bias in the examined pop-
ulations, or real differences due to the eliciting pathogens or
host responses.
Following an outbreak of Q fever in the United Kingdom in
1989, controlled studies showed a high and signiﬁcantly elevat-
ed level of fatigue both 5 and 10 years after the outbreak [36].
No long term follow-up studies of CF elicited by gastroenteritis
have so far been performed. In the present study, the prevalence
of both CF and IBS in the exposed group decreased from 3 to 6
years postexposure. The decrease in prevalence of CF was also
statistically signiﬁcant when compared with the change in the
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control group, whereas the corresponding decrease in IBS prev-
alence did not reach statistical signiﬁcance (Table 4). PI-IBS
thus seems to be more protracted than PI-CF after Giardia
infection.
A large part of the Giardia-exposed individuals who reported
IBS and/or CF in 2007 had persisting complaints also in 2010.
This must be seen in conjunction with the large turnover found
in both examined conditions over the 3-year period, especially
in the control group. Giardia-exposed individuals were more
likely to have had this complication for 3 years already in the
2007 questionnaire study and therefore to have a more estab-
lished condition than controls. So whereas Giardia exposure
is associated with persistence of IBS and CF, the risk may be
overestimated due to initial differences in the exposed and con-
trol groups. Still, we conclude that the individuals with Giardia-
associated IBS and/or CF reported a more persisting phenotype
than controls.
The mechanisms by which a ubiquitous noninvasive intesti-
nal parasite such as G. lamblia may elicit both CF and IBS
remain elusive, but are probably multifactorial. Fatigue syn-
dromes and IBS in general share some predisposing risk markers
such as frequent physician consultations, sickness certiﬁcates,
atopy, mood, and other symptom-based disorders [10]. Most
of these predisposing factors are difﬁcult to assess retrospective-
ly. Atopy was assessed in a previous study in this cohort, and
was found not to be associated with IBS in the Giardia-exposed
group [37]. Genetic vulnerability with polymorphisms in genes
related to epithelial cell barrier function and the innate immune
response could be at play, and have been found in individuals
with IBS after the Walkerton outbreak [38]. The severity of
the eliciting gastroenteritis has been shown to be a risk factor
for development of PI-IBS [39] and has also been found in
this cohort [40]. Protracted Giardia infection and associated
duodenal inﬂammation described by us previously [15] indicate
a strong immune activation in a large proportion of the affected
population that may precipitate long-term sequelae.
Our data are based on a waterborne Giardia outbreak, caus-
ing gastroenteritis in a large population of individuals presumed
not to have been exposed to this parasite previously. This unfor-
tunate event made it possible to study the natural course of IBS
and CF after giardiasis, and shows a signiﬁcantly increased risk
for both IBS and CF even 6 years after the infection.
Based on our ﬁndings, Giardia-induced IBS and/or CF could
be considered a differential diagnosis, especially in returning
travelers who present with such symptoms and where infectious
microorganisms are not detected.
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